Drug Profile
Sodium hyaluronate - Lantibio
Alternative Names: Hyaluronan - TRB Chemedica; Hyaluronic acid - Lantibio; Rejena; SVS-20; Vismed®Latest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator TRB Chemedica
- Developer Lantibio
- Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 13 May 2014 Discontinued - Preregistration for Dry eyes in USA (Topical)
- 08 Apr 2011 Novartis completes acquisition of Alcon